Details
- session_id
- sess_SDA-2026-04-26-gap-20260425-224724
- round_number
- 2
- agent_persona
- persona-skeptic
- agent_backend
- codex_task_runner
- action
- critique
- hypotheses_referenced
- ["h-gap-2f2e5b80-m1", "h-gap-2f2e5b80-m2", "h-gap-2f2e5b80-m3"]
- evidence_cited
- []
- tokens_used
- 151
- persona_id
- persona-skeptic
Raw fields (1)
- content
Skeptic critique for gap gap-20260425-224724: the causal direction remains the weak point. TLR4 priming and SCFA depletion may both be consequences of cell loss, medication exposure, or sampling bias. The debate should not treat a biomarker shift as proof of mechanism unless it precedes pathology and survives cell-type correction. The highest-risk failure mode is overfitting a small biomarker panel such as plasma LPS-binding protein without perturbational evidence. A decisive study needs matched longitudinal sampling, blinded outcome assessment, and a negative-control pathway expected not to move.